文献速递艾滋病与性传播感染

VRC01对B和C亚型HIV-1 Env施加差异压力并在诊断后数周持续

VRC01 exerted differential pressure on HIV-1 Env from subtypes B and C that continued in the first weeks post-diagnosis in the AMP trials.
PubMed 文献 · J Infect Dis · 2026-09-08

基于AMP试验(HVTN 703和HVTN 704),研究者计算VRC01表位距离,比较172名参与者超35,000条Env序列。结果显示VRC01高剂量组表位距离显著大于安慰剂组(p≤0.010),且HVTN 703中VRC01组诊断后首月表位距离变化率显著更高(p≤0.036),提示B和C亚型逃逸路径存在差异。

要点

  • VRC01高剂量组Env表位距离显著大于安慰剂组,提示抗体选择压力。
  • B亚型中部分表位变异被阻断,C亚型中VRC01介导的逃逸影响更强。
  • 选择bnAb开展临床试验时需考虑不同亚型的逃逸路径差异。

核心结论

  • VRC01对B和C亚型HIV-1施加差异选择压力,涉及获毒时筛选和获毒后逃逸效应。

研究设计与样本

  • 基于AMP试验(HVTN 703和HVTN 704)的序列分析,比较172名参与者超35,000条Env的VRC01表位距离。

主要发现

  • 在HVTN 704首次检测到HIV-1时,VRC01高剂量组序列中 distinct VRC01表位较少(p=0.054)。
  • 两个试验中VRC01高剂量组表位距离均显著大于安慰剂组(p≤0.010)。
  • HVTN 703中VRC01组诊断后首月表位距离变化率显著高于安慰剂组(p≤0.036)。

临床怎么用

  • 提示在抗体预防临床试验中需评估亚型特异的逃逸路径。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Antibody Mediated Prevention trials (HVTN 703 and HVTN 704) demonstrated that infusions of the bnAb VRC01 prevented HIV-1 acquisition with viruses sensitive to VRC01 neutralization. We evaluated how VRC01 epitope distances differed across groups in the trials. METHODS: We calculated VRC01 epitope distances (a 3D structure informed measure of how the VRC01 epitope in a sequence differs from that epitope in known VRC01 sensitive strains) to compare >35,000 Envelopes sampled from 172 participants with mostly subtype C viruses in HVTN 703 and subtype B in HVTN 704. RESULTS: At the first visit with detectable HIV-1, we found fewer distinct VRC01 epitopes in the sequences from participants in the VRC01 high-dose group in HVTN 704 (p=0.054), suggesting that some epitope variants were blocked in these participants who harbored subtype B viruses. In both trials, VRC01 epitope distances were significantly larger in the VRC01 high-dose groups than in the placebo groups (p≤0.010). Moreover, sequences sampled in the first month after diagnosis showed that the rate of change in VRC01 epitope distances was significantly higher in the VRC01 groups than in the placebo in the HVTN 703 trial (p≤0.036). CONCLUSIONS: These findings show the impact of sieve acquisition (variants blocked among subtype B viruses) and post-acquisition (stronger impact of VRC01-mediated escape in subtype C) effects, highlighting a complex intersection between HIV-1 subtypes, escape pathways and antibody-mediated prevention. The differential pressure exerted by VRC01 on subtype B vs. C viruses emphasizes that escape pathways need to be considered when selecting bnAbs for clinical trials.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bai H, Juraska M, Magaret CA, et al. VRC01 exerted differential pressure on HIV-1 Env from subtypes B and C that continued in the first weeks post-diagnosis in the AMP trials. J Infect Dis. 2026. PMID: 42708883. doi:10.1093/infdis/jiag454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。